Last reviewed · How we verify
ADX415
ADX415 is a monoclonal antibody targeting CD47.
ADX415 is a monoclonal antibody targeting CD47. Used for Relapsed or refractory acute myeloid leukemia.
At a glance
| Generic name | ADX415 |
|---|---|
| Sponsor | Addrenex Pharmaceuticals, Inc. |
| Drug class | CD47 inhibitor |
| Target | CD47 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By binding to CD47, ADX415 prevents tumor cells from evading immune surveillance, thereby enhancing the body's immune response against cancer cells.
Approved indications
- Relapsed or refractory acute myeloid leukemia
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential Hypertension (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ADX415 CI brief — competitive landscape report
- ADX415 updates RSS · CI watch RSS
- Addrenex Pharmaceuticals, Inc. portfolio CI